VYNE Therapeutics Inc.
VYNE
$1.56
$0.0755.07%
| Weiss Ratings | VYNE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | VYNE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Good | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | VYNE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.70 | |||
| Price History | VYNE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -5.18% | |||
| 30-Day Total Return | -38.29% | |||
| 60-Day Total Return | -43.66% | |||
| 90-Day Total Return | -47.47% | |||
| Year to Date Total Return | -53.30% | |||
| 1-Year Total Return | -48.17% | |||
| 2-Year Total Return | -43.04% | |||
| 3-Year Total Return | -84.31% | |||
| 5-Year Total Return | -98.35% | |||
| 52-Week High % Change | -65.58% | |||
| 52-Week Low % Change | 2.78% | |||
| Price | VYNE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $4.30 | |||
| 52-Week Low Price | $1.44 | |||
| 52-Week Low Price (Date) | Apr 07, 2025 | |||
| 52-Week High Price (Date) | Jan 08, 2025 | |||
| Valuation | VYNE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 21.95M | |||
| Enterprise Value | -39.47M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.94 | |||
| Earnings Per Share Growth | -86.63% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 126.50 | |||
| Price/Book (Q) | 0.42 | |||
| Enterprise Value/Revenue (TTM) | -78.78 | |||
| Price | $1.56 | |||
| Enterprise Value/EBITDA (TTM) | 3.09 | |||
| Enterprise Value/EBIT | 0.90 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | VYNE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 42.60M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | VYNE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 800 775 7936 | |||
| Address | 685 Route 202/206 N Bridgewater, NJ 08807 | |||
| Website | vynetherapeutics.com | |||
| Country | United States | |||
| Year Founded | 2003 | |||
| Profitability | VYNE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -8,709.98% | |||
| Profit Margin | -7,950.89% | |||
| Management Effectiveness | VYNE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -33.14% | |||
| Return on Equity | -- | |||
| Income Statement | VYNE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 501.00K | |||
| Total Revenue (TTM) | 501.00K | |||
| Revenue Per Share | $0.01 | |||
| Gross Profit (TTM) | 501.00K | |||
| EBITDA (TTM) | -12.77M | |||
| EBIT (TTM) | -43.64M | |||
| Net Income (TTM) | -39.83M | |||
| Net Income Avl. to Common (TTM) | -39.83M | |||
| Total Revenue Growth (Q YOY) | 10.53% | |||
| Earnings Growth (Q YOY) | -95.29% | |||
| EPS Diluted (TTM) | -0.94 | |||
| EPS Diluted Growth (Q YOY) | -39.29% | |||
| Balance Sheet | VYNE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 61.52M | |||
| Cash Per Share (Q) | $1.44 | |||
| Total Current Assets (Q) | 64.44M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 52.09M | |||
| Current Ratio (Q) | 4.348 | |||
| Book Value Per Share (Q) | $3.51 | |||
| Total Assets (Q) | 66.91M | |||
| Total Current Liabilities (Q) | 14.82M | |||
| Total Debt (Q) | 99.00K | |||
| Total Liabilities (Q) | 14.82M | |||
| Total Common Equity (Q) | 52.09M | |||
| Cash Flow | VYNE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 23.37M | |||
| Cash from Financing (TTM) | -141.00K | |||
| Net Change in Cash (TTM) | -10.75M | |||
| Levered Free Cash Flow (TTM) | -17.00M | |||
| Cash from Operations (TTM) | -33.97M | |||
